P1, DDI & MAD PK and Safety Study of Xeruborbactam Oral Prodrug in Combo With Ceftibuten in Healthy Participants
Status:
Recruiting
Trial end date:
2024-12-07
Target enrollment:
Participant gender:
Summary
A Phase 1, Open-Label, Drug-drug Interaction, and Randomized, Double-blind, Controlled,
Multiple-dose Pharmacokinetics and Safety Study of Xeruborbactam Oral Prodrug (QPX7831) in
Combination with Ceftibuten in Healthy Adult Participants
Phase:
Phase 1
Details
Lead Sponsor:
Qpex Biopharma, Inc.
Collaborators:
Biomedical Advanced Research and Development Authority Shionogi Inc.